BOSTON, August 26, 2026, 05:20 (EDT)
- CRISPR Therapeutics closed at $60.90, up 6.70% on Tuesday.
- Citizens reiterated an $80 target before Friday’s CTX310 clinical update.
- The company held $2.36 billion of cash and securities at June 30.
CRISPR Therapeutics AG (NASDAQ:CRSP) rose 6.70% before a late-breaking CTX310 presentation. The stock closed Tuesday at $60.90. Volume reached 2.08 million shares.
The $3.83 gain added about $370 million to quoted equity value. Citizens analyst Silvan Tuerkcan reiterated Market Outperform and an $80 target. That target sits 31.4% above Tuesday’s close analyst note.
Investors are paying for Friday’s clinical readout. CRISPR will present durability data for CTX310 at 16:30 CET in Munich. The Phase 1a therapy edits ANGPTL3 inside the liver.
The company now prioritizes severe hypertriglyceridemia and refractory hypercholesterolemia. Both groups carry substantial lifetime cardiovascular risk. A one-time treatment could compete differently from chronic pills, antibodies and RNA therapies.
Friday’s update concerns durability, not approval. CRISPR has already started a Phase 1b trial. U.S. and overseas studies are underway company results.
| Valuation reference | Value | Difference from $60.90 |
|---|---|---|
| Tuesday close | $60.90 | — |
| Citizens target | $80.00 | +31.4% |
| 22-analyst average | $87.56 | +43.8% |
| Consensus median | $80.00 | +31.4% |
| Consensus low | $44.00 | −27.8% |
The wider analyst range shows the event risk. Twenty-two analysts carry a Buy consensus. Their average target is $87.56, while the low estimate is $44 S&P Global data.
CRISPR’s balance sheet can absorb more development. Cash, equivalents and marketable securities totaled $2.36 billion on June 30. That equals 40% of Tuesday’s $5.89 billion market value.
Second-quarter revenue was $10.2 million. The net loss narrowed to $91.2 million from $208.5 million. Research spending was $67.2 million.
At the latest quarterly loss rate, existing cash covers roughly 26 quarters. That simple calculation ignores future trials, manufacturing and convertible-note obligations. Cash increased partly through $585.4 million of note proceeds.
The commercial foundation remains CASGEVY. The therapy generated $76 million of second-quarter revenue, up 78% sequentially. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) leads commercialization and shares program profits and costs 60/40 with CRISPR.
Risks: CTX310 remains investigational and early-stage. Durability can weaken as follow-up extends. Safety findings, smaller lipid reductions or difficult patient selection could reverse Tuesday’s $370 million gain.
The next regular session opens Wednesday at 09:30 EDT. Friday’s 10:30 EDT presentation is the larger valuation test. Investors need persistent ANGPTL3 suppression without a new safety cost.
